The GAAP net income is entirely driven by a non-cash fair value adjustment from the Cobalt amendment, not operational improvement. Monitor the SC451 IND filing and SG293 clinical data in 2027 as key catalysts; cash runway into mid-2027 suggests no near-term financing urgency but burn rate remains elevated.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 6 $2.37entry
- T+1 · 8d ago +4.01%α +1.64% · $2.47
- T+5 · 4d ago −14.77%α −17.36% · $2.02
- T+6 · todayOpen
- T+20 · in 20d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Sana Biotechnology reported Q3 2026 GAAP net income of $20.4 million ($0.07 per share), driven by a $63.4 million non-cash gain from the August 2026 amendment to the Cobalt contingent consideration, versus a net loss of $42.2 million in Q3 2025. Cash position fell to $121.7 million from $138.4 million at year-end 2025, with non-GAAP operating cash burn of $103.4 million for nine months. The company continues to advance SC451 and SG293 toward clinical trials, with IND filing for SC451 expected later this year and SG293 data in first half of 2027.
Key Financial Metrics
Key Facts
- Q3 2026 GAAP net income of $20.4 million ($0.07 per share) vs net loss of $42.2 million ($0.16 per share) in Q3 2025
- Non-GAAP net loss of $43.0 million ($0.14 per share) vs $39.0 million ($0.15 per share) in Q3 2025
- Cash, cash equivalents and marketable securities of $121.7 million as of September 30, 2026, down from $138.4 million at December 31, 2025
- Non-GAAP operating cash burn of $103.4 million for nine months ended September 30, 2026 vs $108.0 million in prior year period
- R&D expenses of $33.9 million in Q3 2026 vs $30.1 million in Q3 2025, driven by SC451 and SG293 manufacturing costs
- Non-cash gain of $63.4 million from change in fair value of success payment liabilities and contingent consideration, including $55.5 million from Cobalt contingent consideration amendment in August 2026
- Cash runway expected into mid-2027
- SC451 IND and Phase 1/2 trial expected as early as this year; SG293 first-in-human data expected in first half of 2027
Financial Impact
GAAP net income of $20.4 million driven by $63.4 million non-cash gain from Cobalt contingent consideration amendment; non-GAAP net loss of $43.0 million; cash burn of $103.4 million YTD
Risk Factors
- Cash burn of $103.4 million YTD with $121.7 million remaining implies potential need for additional capital before mid-2027 if burn rate continues
- SC451 and SG293 are still pre-clinical; clinical trial delays or negative data would remove key catalysts
- Non-GAAP net loss of $43.0 million in Q3 2026 is wider than $39.0 million in Q3 2025, indicating rising operating costs
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-449791 |
| Document: sana-20261105.htm | 0001193125-26-449791 |
| Document: 0001193125-26-449791-index-headers.html | 0001193125-26-449791 |
| Document: 0001193125-26-449791-index.html | 0001193125-26-449791 |
| Document: 0001193125-26-449791.txt | 0001193125-26-449791 |
| 8-K Data (Synthetic) | 0001193125-26-449791 |
Track record
12 reports on SANA
3 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +13.50% at T+20 after the May 11, 2026 report. 3 of 5 went positive at some point.
Filters
- Nov 5, 202611d ago 8-K Neutral 4/10 Viewing Entry $2.37 Now $1.88 −20.68% settles Dec 7
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $2.34 Now $1.88 −19.66% settles Dec 4
- Aug 10, 202614w ago 8-K Neutral 5/10 No price data
- Aug 10, 202614w ago Press Release Neutral 4/10 Entry $3.79 to $3.17 Now $1.88 −50.40% ▼ −16.36% −15.30% vs SPY
- May 11, 202627w ago 8-K Neutral 4/10 No price data
- May 11, 202627w ago Press Release Bearish 6/10 Entry $3.26 to $2.82 Now $1.88 +42.33% ▲ +13.50% +11.77% vs SPY
- Apr 24, 202629w ago DEFA14A Neutral 4/10 Entry $3.29 to $3.15 Now $1.88 −42.86% ▼ −4.26% −8.28% vs SPY
- Apr 24, 202629w ago 8-K Neutral 2/10 Entry $3.29 to $3.15 Now $1.88 −42.86% ▼ −4.26% −8.28% vs SPY
- Apr 13, 202631w ago 8-K Bullish 6/10 Entry $3.48 to $3.56 Now $1.88 −45.98% ▲ +2.30% −4.00% vs SPY
- Apr 13, 202631w ago Press Release Bullish 7/10 Entry $3.48 to $3.56 Now $1.88 −45.98% ▲ +2.30% −4.00% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers